진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적

강현모,이정은,장필순,이연선,권선중,안진영,정성수,김주옥,김선영 충남대학교 암공동연구소 2006 암공동연구소 업적집 Vol.5 No.

Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second -line chemotherapy, for which Docetaxel (Taxotere^(?)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/㎡ or 100 mg/㎡, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression- free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. > 60 years: 6.6 months, p=0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first line platinum -based chemotherapy. (Tuberc Respir DiS 2005: 58: 465-472) 연구배경 : 일차항암화학요법 후에 생존의 이득을 얻었음에도 불구하고 비소세포폐암 환자들의 대다수가 결국은 재발하거나 진행성 병변을 보인다. 이에 저자들은 기존의 여러 연구에서 보고 된 구제요법으로서 docetaxel의 항암효과와 비교적 적은 독성의 결과를 바탕으로,platinum을 근거로 한 항암화학요법을 시행 밖았으나 개발되거나 진행된 비소세포폐암 환자들을 대상으로 docetaxel 단독요법의 치료효과와 부작용에 대하여 알아보고자 하였다. 방법 : 조직학적으로 비소세포폐암으로 진단을 받고 platinum을 근거로 한 항암화학요법을 받았으나 재발 또는 진행성 병변을 보인 31명의 환자들을 대상으로 docetaxel 75 mg/m² 또는 100 mg/m²을 3주마다 정주하였다. 임상기록을 통한 후향적인 방법으로 분석하였다. 결과 : 1) 재발 또는 진행성 병변을 보인 31명중 남녀 비는 24:7이고 중앙연령은 60세였다. 2) 반응평가로 완전 관해는 없었고 부분관해는 14명(45.2%), 불변이 10명(32.3%), 진행이 7명(22.6%)으로 전체적인 반응율은 45.2%이었다. 3)중앙생존기간은 12.5개월(95% 신뢰구간: 7.3개월 17.6개월) 이었고, 1년 생존율은 52%였다. 무진행생존기간의 중앙값은 3.0개월(95%신뢰구간: 1.6개월 -4.5개월)이며, 반응군에서의 중앙반응지속피간은 3.7개월(95% 신뢰구간: 3.0개월 - 4.4개월)이었다. 4) 60세 미만인 경우(20.1 months vs 6.6 months. p=0,0105), 조직학적 아형이 선암일 경우(25.6 months vs 7.9 months, 0=0.0055) 통계적으로 유의한 생존기간의 증가가 있었다. 5) 부작용으로 3도 이상의 백혈구 감소증은 12명(38.7%),호중구 감소증에 동반된 발열은 6명(19.3%),감염이 동반된 호중구 감소증은 4명(12.9%)에서 발생했다. 치료와 관련되어 1명이 사망하였다. 6) Docetaxel 용량에 따른 생존기간의 차이나 독성의 차이는 없었다. 결론 : Platinum을 근거로 하는 항암화학요법으로 치료받은 후 재발 또는 진행성 병변을 보이는 비소세포폐암환자들에게 docetaxel을 투여하는 것은 비교적 안전하고 효과적인 항암치료법으로 사료된다.

진행성 비소세포폐암의 이차항암화학요법으로서 Docetaxel 단독요법의 성적

강현모,이정은,장필순,이연선,권선중,안진영,정성수,김주옥,김선영 충남대학교 암연구소 2006 암연구소 업적집 Vol.5 No.-

Background : The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second -line chemotherapy, for which Docetaxel (Taxotere^(?)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum-based chemotherapy. Methods : Thirty one patients with non-small-cell lung cancer, who had failed first line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/㎡ or 100 mg/㎡, with routine premedication every three weeks. Results : Fourteen patients (45.2%) had a partial response. The median survival and progression- free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age (< 60 years: 20.1 months vs. > 60 years: 6.6 months, p=0.0105) and the histological type (adenocarcinoma: 25.6 months vs. others: 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses. Conclusion : Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small-cell lung cancer who failed first line platinum -based chemotherapy. (Tuberc Respir DiS 2005: 58: 465-472)

구리촉매를 이용한 유기주석화합물 및 유기붕소화합물과 다가 요오드 화합물과의 Cross-Coupling과 Carbonylative Cross-Coupling에 관한 연구

강석구,야마구치토쿠타로,김태현,호필수 성균관대학교 기초과학연구소 1996 論文集 Vol.47 No.2

The copper-catalyzed cross-coupling and carbonylative cross-coupling of organostannanes(aryl-, alkenyl-, alkynyl-, allylstannanes) and anoboranes(aryl-, alkenylboranes)with hypervalent aryl- and alkenyliodonium tetrafluoroborates were achieved at mild conditions.

비소세포 폐암 환자의 이차 치료로서 Gemcitabine과 Vinorelbine 혼합 요법의 효과

장필순,강현모,이정은,권선중,안진영,이연선,정성수,김주옥,김선영 충남대학교 암공동연구소 2006 암공동연구소 업적집 Vol.5 No.

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine 25mg/㎡ followed by an infusion of gemcitabine 1000mg/㎡ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI l-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness. (Tuberc Respir Dis 2005; 58: 344-351) 배경 : Gemcitabine, paditaxel, docetaxel, vinorelbine, ir-rinotecan 새로운 항종양제의 출현으로 일차 치료의효과가 증대 되고 있고 재발시에도 좋은 신체 활동도를 보이고 있어서 이차 치료의 대상군도 늘어나는 효과를 보이고 있다. 치료의 필요성은 증대 되고 있지만 현재까지 표준 치료가 확립되지 않은 상황에서 Gem-citabine과Vinorelbine모두 독성이 강하지 않아서 혼합 요법이 가능한 장점이 있고 비소세포 폐암에 대한효과도 입증이 되어있어서 본 연구는 반응이 없거나 반응을 보인후에 재발된 진행된 비소세포 폐암에 ge-mdtabine과 vinorelbine 흔합 요법을 시행하여서 치료 반응률과 생존율 그리고 부작용을 평가하였다. 대상 및 방법 :2000년 6월부터 2004년 3월까지 충남대학교병원에내원하여 진행성 비소세포 폐암 IIIA/IIIB, IV로 진단을 받고 일차 항암화학요법치료를 받은 환자중에 초기 치료에 반응이 없거나, 치료에 반응이 있었으나 병이 진행된 환자로 추적 관찰 기간이 6개월 이상인 환자를 대상으로 생존율과 반응률 그리고 독성을 분석하였다. 결과 : 총 치료 반응률은 17%. 반응 유지기간의 중앙값은 3.1개월(1-10개월)이었고 생존기간의 중앙값은 8.2개월 (1-23개월) 그리고 1년 생존율은 35%였다. 항암화학요법에 의한 독성은 3도 이상의 중성구 감소가 12%, 오심과 구토가 12.5% 였다. 결론 : 일차 치료에 반응이 없거나 재발한 비소세포 폐암환자의 이차 치료로 gemcitabine과 vinorelbine 혼합요법은 효과적이라고 생각되며 향후 3상 연구를 통한다른 약제와의 비교 연구가 필요하다고 생각된다.

비소세포 폐암 환자의 이차 치료로서 Gemcitabine과 Vinorelbine 혼합 요법의 효과

장필순,강현모,이정은,권선중,안진영,이연선,정성수,김주옥,김선영 충남대학교 암연구소 2006 암연구소 업적집 Vol.5 No.-

Background : Both gemcitabine and vinorelbine are effective anticancer drugs with mild toxicity on non-small cell lung cancer, and monotherapy of these drugs are effective as a second-line chemotherapy. The aim of this trial was to assess the response and toxicity of a combination of gemcitabine and vinorelbine in patients of previously treated for non-small cell lung cancer. Materials and Methods : 24 patients, initial stage III A/B,IV and previously treated with platinium and taxane based regimens, were enrolled from June 2000 to March 2004. The regimens consisted of vinorelbine 25mg/㎡ followed by an infusion of gemcitabine 1000mg/㎡ on day 1 and day 8 every three weeks. This course was repeated more than twice. Results : Twenty-four patients were analyzed for the response, survival rate, and toxicities. The overall response was 17% with a complete remission rate of 4%. The median time-to progression (TTP) was 3.1 months (95%, CI l-10months), and the survival time was 8.2 months (95%, CI 1-23 months). The grade 3/4 toxicities encountered were neutropenia (12.5%), anemia (0%), thrombocytopenia (0%). Non-hematological 3/4 toxicities were not observed. Conclusion : A combination of gemcitabine and vinorelbine in patients previously treated for non-small cell lung cancer provides a relatively good response rate, and a low toxicity profile. However, further study will be needed to confirm its effectiveness. (Tuberc Respir Dis 2005; 58: 344-351)

일개 대학병원에 내원한 원발성 폐암 환자의 인구학적 및 병리학적 특성

주혜원,강경필,김민근,박민석,임현민,이현경,이성순,이영민,김주인,염호기,최수전,이혁표 인제대학교 2006 仁濟醫學 Vol.27 No.-

Background : Recently, the lung cancer mortality rank first in Korea. The prognosis of lung cancer is not good enough with current treatments and multimodality treatments are required. So we are interested in the characteristics of lung cancer patients for better treatment. Methods : We searched lung cancer patients since 1994. Then we collected the data of primary lung cancer patients about the demographic features, histologic types and diagnotic methods. We divided the total period into 2 haves and specific analysis was tried. Results : 1) Total 850 patients were included. 633 (74.5%) were male and 217 (25.5%) were female. 2) The mean age was 65 ± 11 years old. and the peak age was 7th decades. 3) Squamous cell carcinoma(334/850, 39.3%) was slightly more prevalent than adenocarcinoma(302/850, 35.5%). Conclusion : From these results, we expected that older persons will be diagnosed to have lung cancer and adenocarcinoma will be more dominant histologic type with time.

브러시리스 DC 모터의 코킹토크 저감 대책

서기영,이현우,문상필,강욱중 慶南大學校 附設 工業技術硏究所 1999 硏究論文集 Vol.17 No.-

본 연구에서는 정밀, 소형제동에 사용되는 브러시리스 DC모터의 정밀 운전시 문제가 되는 코킹 토크의 저감을 위하여 코킹 토크 형성에 관한 특정식을 유도하여 그 성질을 파악하고 특정식을 토대로 코킹 토크저감을 위한 설계법을 제안하였다. The Paper characteristics equation of cogging torque is induced to learn this characteristics and on the ground of this equation, the design method is proposed for reducing cogging torque which is the problem to precisely drive DC brushless motor used in precise control system.

한국에서의 스페인 연구 60년사 : 동향과 과제

최윤국,김현식,강필운,양성혜 조선대학교 국제문화연구원 2008 국제문화연구 Vol.1 No.1

Este trabajo trata de ojear la historia de las investigaciones con los temas de Espan~a realizadas en Corea durante unos 60 an~os. Para dicho objetivo elaboramos una base de datos de la bibliografi'a que abarca todos los libros, arti'culos, tesis sobre Espan~a publicados en Corea desde el an~o 1945 hasta el 2007. Basa'ndonos en el cual analizamos la tendencia del estudio espan~ol en Corea. La suma de los estudios realizados en Corea durante tal peri'odo llega a ser 3,072 ejemplares, entre los cuales, los libros son 1,131(36.82%), las tesis, 612(19.92%) y los arti'culos acade'micos, 1,329(43.26%). Analizando los datos, primero, esbozamos co'mo se han cambiado por las etapas el nu'mero de los frutos de las investigaciones espan~olas en Corea a lo largo del tiempo, segundo, nos centramos en la transicio'n por peri'odo del porcentaje que ocupan cada campos de estudio. por ejemplo, en poli'tica, economi'a, cultura, sociedad, historia, geografi'a, lingu¨i'stica y literatura, turismo, etc. y el cambio de los contenidos de estudio en cada campos segu'n las etapas del tiempo. Una peculiaridad destacable en el resultado del ana'lisis es que han estimulado la investigacio'n sobre Espan~a en Corea unos eventos histo'ricos en ambos pai'ses como la imigracio'n de coreanos a los pai'ses hispanohablantes, la poli'tica de la campan~a de exportacio'n por parte del gobierno coreano, la adhesio'n de Espan~a en la CE en 1986, los Juegos Oli'mpicos en Seu'l en 1988, la asociacio'n de Corea tanto en la OCDE como en la ASEM en 1996, la Copa Mundial de Fu'tbol en Corea en 2002, etc.

數 種 韓藥의 아세틸콜린에스터레이즈 酵素活性에 대한 효과

최재환,김미영,김현미,최훈,전훈,김대근,임종필,임강현 대한본초학회 2002 大韓本草學會誌 Vol.17 No.1

아세틸콜린에스터레이즈(AChE)는 신경조직에 분포하는 효소로 신경전달물질 중 아세틸콜린(ACh)을 분해하는 효소로 시냅스 신호전달체계에 있어 중요한 역할을 하는 효소이다. 현재 알츠하이머병과 치매치료에 사용하는 서양약물은 AChE의 활성을 저해하는 작용기전을 가진다. 목적 : 전통적으로 기억력 감퇴, 치매 등 치료에 사용되어 온 한약의 AChE에 대한 작용을 밝히기 위해 본 실험이 구상되었다. 방법 : 생쥐 대뇌신경세포의 균질 혼합액으로부터 효소의 활성을 Ellman 방법을 개선한 엘리자(ELISA)법을 이용하여 측정하였다. 결과 : 실험결과 天花? 의 6종이 2.5㎎/㎖의 농도에서 우수한 효소활성저해력을 보였고, 50% 효소활성 저해농도(ID_50)를 구한 결과, 天花?의 ID_50은 1.5㎎/㎖이었고, ??? 1.2 ㎎/㎖, ?? 2.0 ㎎/㎖, ??草 1.2 ㎎/㎖, ??? 1.0 ㎎/㎖, ??生 1.7㎎/㎖, 및 大?皮 2.0 ㎎/㎖를 나타내어 忍冬?의 저해력이 가장 우수하였다. 결론 : 치매 및 기억력감퇴 증상을 치료하는 한약의 작용기전 중 AChE 효소활성억제효과는 忍冬? 의 6종에서 나타났으며, 이는 전통적인 한방치료에 과학적인 기초자료를 제공할 것으로 생각한다.

Pathogenomics of Streptococcus ilei sp. nov., a newly identified pathogen ubiquitous in human microbiome

Hyun Dong-Wook,Lee Jae-Yun,Kim Min-Soo,Shin Na-Ri,Whon Tae Woong,Kim Kyung Hyun,Kim Pil Soo,Tak Euon Jung,Jung Mi-Ja,이준영,Kim Hyun Sik,Kang Woorim,Sung Hojun,Jeon Che Ok,Bae Jin-Woo 한국미생물학회 2021 The journal of microbiology Vol.59 No.8

Viridans group streptococci are a serious health concern because most of these bacteria cause life-threatening infections, especially in immunocompromised and hospitalized individuals. We focused on two alpha-hemolytic Streptococcus strains (I-G2 and I-P16) newly isolated from an ileostomy effluent of a colorectal cancer patient. We examined their pathogenic potential by investigating their prevalence in human and assessing their pathogenicity in a mouse model. We also predicted their virulence factors and pathogenic features by using comparative genomic analysis and in vitro tests. Using polyphasic and systematic approaches, we identified the isolates as belonging to a novel Streptococcus species and designated it as Streptococcus ilei. Metagenomic survey based on taxonomic assignment of datasets from the Human Microbiome Project revealed that S. ilei is present in most human population and at various body sites but is especially abundant in the oral cavity. Intraperitoneal injection of S. ilei was lethal to otherwise healthy C57BL/6J mice. Pathogenomics and in vitro assays revealed that S. ilei possesses a unique set of virulence factors. In agreement with the in vivo and in vitro data, which indicated that S. ilei strain I-G2 is more pathogenic than strain I-P16, only the former displayed the streptococcal group A antigen. We here newly identified S. ilei sp. nov., and described its prevalence in human, virulence factors, and pathogenicity. This will help to prevent S. ilei strain misidentification in the future, and improve the understanding and management of streptococcal infections.